
Please try another search
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
A. Machelle Sanders | 61 | 2024 | Independent Director |
Edward A. Pesicka | 57 | 2023 | Independent Director |
David Ross Smith | 59 | 2023 | Independent Director |
Amrit Ray | 52 | 2023 | Independent Director |
Erin L. Russell | 50 | 2025 | Independent Director |
Peter M. Neupert | 69 | 2023 | Interim CEO, Chairman of the Board & Lead Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review